Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

CHC / By

Limousin W, Laurent-Puig P, Ziol M, Ganne-Carrié N, Nahon P, Ait-Omar A, Seror O, Sidali S, Campani C, Blanc P, Lermine A, Marisa L, Zucman-Rossi J, Nault JC.J Hepatol. 2023 Dec;79(6):1450-1458. doi: 10.1016/j.jhep.2023.08.017. Epub 2023 Aug 28.PMID: 37647991 Background & aims: The “French Medicine Genomic program 2025” has been designed to give patients with cancers …

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab Read More »

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis

CHC / By

Nahon P, Bamba-Funck J, Layese R, Trépo E, Zucman-Rossi J, Cagnot C, Ganne-Carrié N, Chaffaut C, Guyot E, Ziol M, Sutton A, Audureau E; ANRS CO12 CirVir and CIRRAL groups. J Hepatol. 2023 Mar;78(3):584-595. doi: 10.1016/j.jhep.2022.11.003. Background & aims: Identifying individuals at higher risk of developing hepatocellular carcinoma (HCC) is pivotal to improve the performance …

Integrating genetic variants into clinical models for hepatocellular carcinoma risk stratification in cirrhosis Read More »

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis

CHC, Cirrhose / By

Nahon P, Layese R, Ganne-Carrié N, Moins C, N’Kontchou G, Chaffaut C, Ronot M, Audureau E, Durand-Zaleski I, Natella PA; ANRS CO12 CirVir and CIRRAL groups. Hepatology. 2023 Sep 29. doi: 10.1097/HEP.0000000000000615. Background and aims: Hepatocellular carcinoma (HCC) surveillance is challenged by the detection of hepatic focal lesions (HFLs) of other types. This study aimed …

The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis Read More »

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort

Cirrhose / By

Louvet A, Bourcier V, Archambeaud I, d’Alteroche L, Chaffaut C, Oberti F, Moreno C, Roulot D, Dao T, Moirand R, Duclos-Vallée JC, Goria O, Nguyen-Khac E, Pol S, Carbonell N, Gournay J, Elkrief L, Fouchard-Hubert I, Chevret S, Ganne-Carrié N; CIRRAL group. J Hepatol. 2023 Mar;78(3):501-512. doi: 10.1016/j.jhep.2022.11.013. Epub 2022 Nov 22. Background & aims: …

Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort Read More »

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab

CHC / By

Campani C, Bamba-Funck J, Campion B, Sidali S, Blaise L, Ganne-Carrié N, Demory A, Sutter O, Larrey E, Evain M, Ghannouchi H, Wagner M, Marra F, Sutton A, Allaire M, Nault JC. Liver Int. 2023 Mar;43(3):708-717. doi: 10.1111/liv.15487. Epub 2022 Dec 14. Background: The combination of atezolizumab and bevacizumab (AtezoBev) is the current first-line treatment …

Baseline ALBI score and early variation of serum AFP predicts outcomes in patients with HCC treated by atezolizumab-bevacizumab Read More »

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022)

CHC / By

Sidali S, Sritharan N, Campani C, Gregory J, Durand F, Ganne-Carrié N, Ronot M, Lévy V, Nault JC. JHEP Rep. 2023 Apr 7;5(7):100755. doi: 10.1016/j.jhepr.2023.100755. Background & aims: The fragility index (FI), i.e., theminimum number of best survivors reassigned to the control group required to revert the statistically significant result of a clinical trial to …

Fragility index of positive phase II and III randomised clinical trials of treatments for hepatocellular carcinoma (2002-2022) Read More »

Benign liver tumours: understanding molecular physiology to adapt clinical management

Adénome hépatocellulaire / By

Nault JC, Paradis V, Ronot M, Zucman-Rossi J. Abstract Improvements in understanding the pathophysiology of the different benign liver nodules have refined their nosological classification. New criteria have been identified using imaging, histology and molecular analyses for a precise diagnosis of these tumours. Improvement in the classification of liver tumours provides a more accurate prediction …

Benign liver tumours: understanding molecular physiology to adapt clinical management Read More »

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation

Adénome hépatocellulaire / By

Demory A, Péron JM, Calderaro J, Selves J, Mokrane FZ, Amaddeo G, Paradis V, Ziol M, Sutter O, Blaise L, Ganne-Carrié N, Vilgrain V, Cauchy F, Zucman-Rossi J, Ronot M, Nault JC Background and aims: The natural history of hepatocellular adenomas (HCAs) remains to be better described, especially in nonresected patients. We aim to identify the predictive …

Body weight changes and duration of estrogen exposure modulate the evolution of hepatocellular adenomas after contraception discontinuation Read More »

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis

CHC / By

Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. Abstract Background & aims: There is controversy regarding the overall value of hepatocellular carcinoma (HCC) surveillance in patients with cirrhosis given the lack of data from randomized-controlled trials. To address this issue, we …

HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis Read More »

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts

Cirrhose / By

Ollivier-Hourmand I, Repesse Y, Nahon P, Chaffaut C, Dao T, Nguyen TTN, Marcellin P, Roulot D, De Ledinghen V, Pol S, Guyader D, Archambeaud I, Zoulim F, Oberti F, Tran A, Bronowicki JP, D’Alteroche L, Ouzan D, Peron JM, Zarski JP, Bourliere M, Larrey D, Louvet A, Cales P, Abergel A, Mathurin P, Mallat A, …

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts Read More »